Rise and shine. Another day is on the way. And we are getting started by hustling short people off to school houses and, of course, quaffing a cup or two of stimulation. How else to cope? We trust you know the feeling. Meanwhile, there are meetings and deadlines that are looming. To get you started, here are some tidbits from around the world. Have a great day and stay in touch...
Pfizer Strikes Deal With Parexel For CRO Services (Outsourcing Pharma)
Bayer To Close California Plant And Axe 540 Jobs (San Francisco Business Times)
Women With High Co-Pays Likelier To End Breast Cancer Drugs (Reuters)
Johnson & Johnson Gives Drug Pipeline Progress Report (Associated Press)
Pfizer Has Tough Pricing Decision For Its New Arthritis Pill (Reuters)
World Health Organization Reviews Reform Process (ICTSD Bridges Weekly)
Merck KGgA To Promote Childbirth In Korea (Korea Herald)
UCB To Test Arthritis Drug Against Abbott's Humira (London South East)
Pharma Urges EU Not To Revise Transparency Directive (Pharma Times)
Does Aspirin Really Cut Deaths? (Reuters)
EDITOR’S NOTE: Please check this post for updates throughout the morning
2 Comments
Bayer is way behind the times. In my consulting work I have been hooking up sponsors with contract manufacturers (cGMP credentialed of course) exclusively for the past 11 years. Once I show them the cost benefits of actually doing the work outside their own shop, and once they get around the internal politics, I'm usually able to shave them 20-30% of time to market, and in this business time is money.
Industry insider.... can you shed any light on the profit involved and pharma drive for the use of epidurals during childbirth? Warm regards